Abbott, Reckitt Benckiser’s Mead Johnson NEC Litigation: BI Webinar

On Demand

Duration: 53 Minutes

Original Date: September 25, 2024

First name

Last name

Email address

Business phone

Company

Job role

Industry

City

Country or Region

State or Province Optional

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Holly Froum, BI Litigation Analyst, will discuss federal and state litigation against Abbott and Reckitt's Mead Johnson over claims preterm infant formula causes necrotizing entereocolitis (NEC) in preterm infants. She will talk about a Sept. 30 trial that’s to be held in the same jurisdiction that delivered a $500 million verdict against Abbott, potential exposure and other key dates in the litigation. Diana Gomes, Senior Consumer Health Analyst, will discuss implications and valuation scenarios of a potential sale of Mead Johnson (leading US baby formula business, with £2.4 billion in 2023 revenue), as Reckitt is reviewing exit options to bolster its margin.

Abbott, Reckitt Benckiser’s Mead Johnson NEC Litigation: BI Webinar

Access a broad range of analysis, research, insight and actionable ideas with Bloomberg webinars.